Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 60/100

Failure Rate

14.3%

1 terminated/withdrawn out of 7 trials

Success Rate

83.3%

-3.2% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

0 of 5 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 1

4(57.1%)

Phase 2

2(28.6%)

N/A

1(14.3%)

7Total

Phase 1(4)

Phase 2(2)

N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials

NCT04933916Phase 1Terminated

Study of EMB-001 as a Potential Smoking Cessation Treatment

Role: lead

NCT04501874Phase 2Completed

A Study to Evaluate EMB 001 in Subjects With Cocaine Use Disorder

Role: lead

NCT04868253Phase 2Unknown

Efficacy and Safety of Combination EMB-001 as a Potential Smoking Cessation Treatment

Role: collaborator

NCT03404817Phase 1Completed

Single Dose Crossover Comparative Bioavailability and Food Effect Study of Two EMB-001 Formulations

Role: lead

NCT02856854Phase 1Completed

A Study of Metyrapone and Oxazepam Combination Product (EMB-001) and Cocaine

Role: lead

NCT02406066Phase 1Completed

Single and Multiple Rising Dose Study of Safety and PK of Metyrapone/Oxazepam Combination (EMB-001)

Role: lead

NCT00567814Not ApplicableCompleted

A Placebo-Controlled Study of a Combination of Metyrapone and Oxazepam in Cocaine Addiction

Role: lead

All 7 trials loaded